Literature DB >> 20187229

Clues to how alpha-synuclein damages neurons in Parkinson's disease.

David Sulzer1.   

Abstract

Alpha-synuclein (alpha-syn) appears to normally regulate neurotransmitter release, possibly via calcium-dependent binding and dissociation from lipid domains on secretory vesicles. The pathogenic effects of alpha-syn leading to Parkinson's disease (PD) appear to result from alternate toxic effects on lipid membrane. A variety of findings indicate that overexpression of wild-type alpha-syn, pathogenic mutations of alpha-syn, and dopamine-modified-alpha-syn promote toxic interaction between alpha-syn oligomers and lipids. These may disrupt transmembrane concentration gradients across secretory vesicles and other organelles and interfere with normal lysosomal or ubiqutin/proteasome mediated protein degradation or mitochondrial function. Additional causes of PD may interfere at other points with normal handling and degradation of alpha-syn, providing a variety of entry points to a converging neurodegenerative path underlying the disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20187229     DOI: 10.1002/mds.22639

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  15 in total

Review 1.  Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences.

Authors:  Nicole Exner; Anne Kathrin Lutz; Christian Haass; Konstanze F Winklhofer
Journal:  EMBO J       Date:  2012-06-26       Impact factor: 11.598

2.  Secrets of the shaking palsy.

Authors:  Jim Schnabel
Journal:  Nature       Date:  2010-08-26       Impact factor: 49.962

Review 3.  Parkinson's disease dementia and potential therapeutic strategies.

Authors:  John N Caviness; LihFen Lue; Charles H Adler; Douglas G Walker
Journal:  CNS Neurosci Ther       Date:  2010-12-28       Impact factor: 5.243

Review 4.  Trehalose as a promising therapeutic candidate for the treatment of Parkinson's disease.

Authors:  Masoomeh Khalifeh; George E Barreto; Amirhossein Sahebkar
Journal:  Br J Pharmacol       Date:  2019-03-27       Impact factor: 8.739

5.  A novel "molecular tweezer" inhibitor of α-synuclein neurotoxicity in vitro and in vivo.

Authors:  Shubhangi Prabhudesai; Sharmistha Sinha; Aida Attar; Aswani Kotagiri; Arthur G Fitzmaurice; Rajeswari Lakshmanan; Ravi Lakshmanan; Magdalena I Ivanova; Joseph A Loo; Frank-Gerrit Klärner; Thomas Schrader; Mark Stahl; Gal Bitan; Jeff M Bronstein
Journal:  Neurotherapeutics       Date:  2012-04       Impact factor: 7.620

6.  Selective α-Synuclein Knockdown in Monoamine Neurons by Intranasal Oligonucleotide Delivery: Potential Therapy for Parkinson's Disease.

Authors:  Diana Alarcón-Arís; Ariadna Recasens; Mireia Galofré; Iria Carballo-Carbajal; Nicolás Zacchi; Esther Ruiz-Bronchal; Rubén Pavia-Collado; Rosario Chica; Albert Ferrés-Coy; Marina Santos; Raquel Revilla; Andrés Montefeltro; Isabel Fariñas; Francesc Artigas; Miquel Vila; Analia Bortolozzi
Journal:  Mol Ther       Date:  2017-11-29       Impact factor: 11.454

7.  Upregulation of α-synuclein during localized radiation therapy signals the association of cancer-related fatigue with the activation of inflammatory and neuroprotective pathways.

Authors:  L N Saligan; C P Hsiao; D Wang; X M Wang; L St John; A Kaushal; D Citrin; J J Barb; P J Munson; R A Dionne
Journal:  Brain Behav Immun       Date:  2012-09-26       Impact factor: 7.217

8.  Glycation of α-synuclein hampers its binding to synaptic-like vesicles and its driving effect on their fusion.

Authors:  Ana Belén Uceda; Juan Frau; Bartolomé Vilanova; Miquel Adrover
Journal:  Cell Mol Life Sci       Date:  2022-06-04       Impact factor: 9.207

9.  Axonopathy in an α-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated α-synuclein.

Authors:  Dora Games; Peter Seubert; Edward Rockenstein; Christina Patrick; Margarita Trejo; Kiren Ubhi; Benjamin Ettle; Majid Ghassemiam; Robin Barbour; Dale Schenk; Silke Nuber; Eliezer Masliah
Journal:  Am J Pathol       Date:  2013-01-09       Impact factor: 4.307

10.  In vivo electrophysiology of nigral and thalamic neurons in alpha-synuclein-overexpressing mice highlights differences from toxin-based models of parkinsonism.

Authors:  C J Lobb; A K Zaheer; Y Smith; D Jaeger
Journal:  J Neurophysiol       Date:  2013-09-25       Impact factor: 2.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.